TrialAntimicrobial agents and chemotherapy2025

Single- and multiple-dose pharmacokinetics and safety of the SARS-CoV-2 3CL protease inhibitor RAY1216: a phase 1 study in healthy participants.

Yue Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.